Can rucaparib treat small cell lung cancer?

Rucaparib (Rucaparib) is not currently approved for the treatment of small cell lung cancer. Up to now, rucapanib has been mainly approved for the treatment of ovarian cancer, prostate cancer and other cancers carrying BRCA gene mutations or HRD (familial repair defect) gene mutations. For the treatment of small cell lung cancer, current standard treatment options usually include chemotherapy, radiotherapy, and surgery. While PARP inhibitors have shown therapeutic potential in certain cancer types, their use in small cell lung cancer is still in the investigational stage.

Rucaparib is available by prescription only, and treatment should be initiated and supervised by a physician experienced in treating cancer. Rucaparib is available as a tablet and should be taken twice daily. Treatment should be continued until the cancer progresses or the patient experiences unacceptable side effects. Treatment with rucapanib should be started within 8 weeks after the patient completes platinum-based therapy. The most common side effects of rucapanib (which may affect more than 1 in 5 people) include fatigue or weakness, nausea, vomiting, anemia, abdominal pain (stomach pain), dysgeusia, elevated levels of liver enzymes in the blood, decreased appetite, diarrhea, and thrombocytopenia.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani original drug, specifications300mg*60 tablets sold overseas may cost more than 20,000 yuan per box (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).